Danish medical device maker Ambu on Wednesday reported double-digit revenue growth for its 2024/25 fiscal year and launched a new strategy aimed at achieving global leadership in the single-use endoscopy market.
The company said it posted organic revenue growth of 13.1% for the year ended Sept. 30, driven by a 15.4% increase in its Endoscopy Solutions division and a 9.9% rise in its Anesthesia & Patient Monitoring business.
Ambu's operating profit margin before special items reached 13.0%, according to its annual report.
The results mark the conclusion of its 'ZOOM IN' turnaround plan, setting the stage for its new 'ZOOM AHEAD' strategy.
“We have delivered another strong year at Ambu of double-digit organic growth and profitability, successfully concluding our turnaround with our ZOOM IN strategy and setting the stage for what’s next,” Chief Executive Britt Meelby Jensen said.
For the 2025/26 fiscal year, Ambu guided for organic revenue growth of 10% to 13%.
It expects an operating profit margin of 12% to 14%, noting the figure is impacted by an estimated two percentage points from tariffs.
Ambu also proposed a total cash distribution of 260 million Danish kroner, consisting of a dividend and a share buy-back program.
More from this issuer
Related coverage
Danish medical device maker Ambu A/S on Wednesday launched a new strategy aimed at achieving global leadership in the single-use endoscopy market as it reported full-year results in line with its guidance.
Danish medical device maker Ambu A/S on Tuesday raised its long-term growth targets as part of a new strategic plan, building on what it called a successful financial turnaround.
Medical device maker Ambu A/S on Friday cut its full-year free cash flow forecast, citing negative impacts from foreign exchange rates and tariff costs, even as it reported solid quarterly growth.